KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Common Equity: 2010-2024

Historic Common Equity for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to $27.4 million.

  • TherapeuticsMD's Common Equity rose 1.29% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 1.29%. This contributed to the annual value of $27.4 million for FY2024, which is 6.55% down from last year.
  • Per TherapeuticsMD's latest filing, its Common Equity stood at $27.4 million for FY2024, which was down 6.55% from $29.3 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's Common Equity ranged from a high of $35.1 million in FY2022 and a low of -$124.0 million during FY2020.
  • In the last 3 years, TherapeuticsMD's Common Equity had a median value of $29.3 million in 2023 and averaged $30.6 million.
  • As far as peak fluctuations go, TherapeuticsMD's Common Equity slumped by 1,447.69% in 2020, and later spiked by 137.54% in 2022.
  • Yearly analysis of 5 years shows TherapeuticsMD's Common Equity stood at -$124.0 million in 2020, then climbed by 24.50% to -$93.6 million in 2021, then soared by 137.54% to $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then fell by 6.55% to $27.4 million in 2024.